Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Qian Wang, Jianqiu Wu et al.|Journal of Hematology & Oncology|2021Cited by 64
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Jun Zhu, Kaiyang Ding et al.|The Lancet Oncology|2023Cited by 61
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera <sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trialYuankai Shi, Yanan Ji, Qingyuan Zhang et al.|Hematological Oncology|2022Cited by 9
Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III StudyFeng Xue, Renchi Yang, Hu Zhou et al.|Blood|2022Cited by 0